Pacira shares price target cut amid patent litigation

On Monday, H.C. Wainwright adjusted its stock price target for Pacira Pharmaceuticals (NASDAQ:PCRX) to $39.00, down from the previous $57.00, while maintaining a Buy rating on the stock. The revision follows a recent legal setback for Pacira in a patent dispute over its drug Exparel.

On Friday, a District Court ruled that the '495 patent held by Pacira was invalid due to being obvious and anticipated, a decision that came as a disappointment to the company and its investors who had hoped for a ruling of validity and infringement.

Despite this unfavorable outcome, the analyst at H.C. Wainwright believes that the decision is not a critical blow to Exparel or Pacira's future. The court did not find any inequitable conduct by Pacira, and the company still has four additional Orange Book-listed patents, expiring in 2041, which are currently in the early stages of litigation against eVenus, the generic challenger. These patents are presumed valid and are not affected by the recent ruling.

Pacira has expressed confidence that sealed information from the '495 litigation strongly suggests that eVenus is likely infringing on the later patents. Contrary to some reports that a generic version of Exparel might launch as early as this year, the analyst anticipates that the risk of a launch during ongoing litigation would be unlikely, pushing a potential generic launch free from the risk of triple damages to at least mid-2026.

The analyst also suggests that the current market valuation of Pacira reflects expectations of an imminent generic launch, which they consider inaccurate. In light of the recent developments, H.C. Wainwright has recommended strong buying of Pacira stock at its current valuation and would view aggressive stock buybacks by the company as a positive move.

The revised price target of $39.00 is intended to account for some possibility of earlier generic competition while reaffirming the firm's Buy rating on Pacira shares.

In other recent news, Pacira Pharmaceuticals has been the subject of several analyst downgrades, following a legal setback involving its flagship product, Exparel. RBC Capital downgraded Pacira's stock from Outperform to Sector Perform, reducing the price target to $14 from the previous $37. Similarly, Raymond James, Piper Sandler, and JPMorgan all downgraded their ratings of Pacira's stock, citing the invalidation of the '495 patent on Exparel as the cause.

Despite these developments, Pacira reported Q1 2024 revenue of $149 million, with Exparel contributing $118 million. Furthermore, the company launched a private placement of $250 million in convertible senior notes due in 2029, projected to yield net proceeds of approximately $242 million. Amid this situation, the perspectives of analysts vary, with firms such as Piper Sandler and H.C. Wainwright maintaining a positive outlook on Pacira.

These recent developments highlight the evolving situation at Pacira Pharmaceuticals, as the company grapples with legal and competitive challenges. CEO Frank D. Lee expressed confidence in the company's intellectual property portfolio and indicated plans to consider an appeal. The company's ongoing patent litigations and management changes are also significant recent developments.

InvestingPro Insights

As the market digests the implications of Pacira Pharmaceuticals' (NASDAQ:PCRX) recent patent dispute outcome, investors may find value in considering the latest data and insights provided by InvestingPro. The company's management has been proactive in capitalizing on the current stock valuation, with aggressive share buybacks signaling confidence in the company's financial health and future prospects. Moreover, the current market valuation may not fully reflect Pacira's growth potential, as net income is expected to grow this year and analysts have revised their earnings upwards for the upcoming period.

InvestingPro Data reveals a P/E ratio of 15.9, indicating a reasonable valuation relative to earnings, and a robust gross profit margin of 62.99% for the last twelve months as of Q2 2024, underscoring the company's ability to maintain profitability. The stock's significant price drop over the last week and month positions it in what some analysts might consider oversold territory, potentially offering an attractive entry point for investors.

For those seeking additional insights, InvestingPro offers a comprehensive list of tips, including the fact that the company is expected to remain profitable this year and that its liquid assets exceed short-term obligations. These insights, along with 13 additional InvestingPro Tips, can be found at: https://www.investing.com/pro/PCRX, providing investors with a deeper understanding of the investment opportunity at hand.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.